已阅读5页,还剩16页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
HEART FAILURE,Management of Heart Failure,Treatment Strategies: Ameliorate symptoms Maintain cardiac functional state Reduce mortality rate Reduce hospitalization,Treatment,1. The cause must be removed 2. General management: bed rest, mitigate,oxygen inhalation, reduction of salt intake 3. Drug Treatment,Drug Treatment,Positive inotropic agentscardiac glycosides, phosphodiesterase inhibitorsVasodilatorsDiureticsAngiotensin converting enzyme inhibitors (ACEI)Beta-blockers,治疗,洋地黄类药物:正性肌力,负性传导,负性心率;直接抑制过度的神经内分泌系统。临床常用制剂:地高辛;西地兰。常用剂量:地高辛口服化量:2岁0.05-0.06mg/kg,2岁0.03-0.05mg/kg,维持量为化量的1/5。西地兰静注化量:2岁0.03-0.04mg/kg,2岁0.02-0.03mg/kg。 新生儿用量更少,取婴儿量的1/2至2/3。,治疗-洋地黄类药物,使用方法 化量(饱和量):适用于急性心衰或重症心衰,首次用化量的1/2量,余量分2次(1/4、1/4), q4h-q6h或q8h。 维持量:适用于慢性心衰或轻症心衰,维持量为化量的1/5量,分2次口服;或者化量后需继续维持者,于化量后12小时开始予维持量。,治疗-洋地黄类药物,注意事项:用药前了解洋地黄情况;避免用钙剂;注意纠正低血钾。洋地黄中毒 表现:心律失常;消化道症状;神经系统症状等。 处理:停用洋地黄及利尿剂;口服补钾;必要时用抗心律失常药。,Diuretics,Relieve the congestion status by elimination of sodium and water.Indicated in pulmonary congestion with dyspnea and rales and generalized edema ,ascitesAgents used:Thiazideschlorothiazide , chlothalidoneLoop diureticsfurosimide, bumetanide, ethacrynic acidPotassium-sparing diureticsspirolectone, triamterene, amilorideSide effects: hypokalemia, hyperglycemia,ACE-Inhibitors,Rationales of the ACEI treatment for heart failure:Decreases peripheral circulatory resistanceDecreases the blood volumeDecreases the sympathetic activityInhibition of the remodeling process,ACE-Inhibitors,Short-term effectsSymptomatic improvement: approximately 2/3 of cases with severe heart failure show diurea, improvement in dyspnea and less edema.Hemodynamic improvement: increased cardiac output by 25%-30% reduction of PCWP by 20% decreased peripheral resistance by 30% BPdrop 10%-15% Heart rateslightly reducsedN.B. 1st dose hypotension, transient elevation of BUN and creatinin,ACEI treatment of H.F.,Long-term effects : Reduction of mortality and preservationof cardiac function.SAVE study: Cases: post acute myocardial infarction with EF40% Captopril Control PCase No. 1115 1116Mortality rate(42months) RR21% 0.014DevelopmentOf severe H.F. RR 37% 0.001,SOLVE study:,1) Cases of H.F.with symptoms, EF35%Enalapril ControlCase No. 2111 2117 Follow up for 37.4 monthsReduction of the death or development of H.F.by 37% (P0.001),Conclusion of ACEI treatment of heart failure:,ACEI should be used in patients with heart failure irrespective to their underlying causes, if not contra-indicated.Early application of ACEI can postpone the development of congestive heart failureAttention should be paid to hypotension, increased blood Cr content and the side effect of cough.Agent used: Captopril, Enalapril, Perindopril, Lisinopril etc.,Beta-blocker in treatment of H.F.,Adverse effects induced by prolonged excessive sympathetic activity:Increases peripheral resistance-after-loadIncreases heart rateIncreases excitability-arrhythmiasElevation of NE cAMP intracellular Ca+ overload precipitation of apoptosis and cell deathBeta-blockers can induce negative inotropic response,Clinical Trial: US Carvedilol Heart Hailure Study,Carvedilol Placebo RR PNo.of cases 696 398Mortality rate (%) 3.2 7.8 65% 0.001Hospitalization (%) 14.1 19.6 27% 0.036Agents proved to be effective in major clinical trails: Carvedilol, Metaprolol, Bisoprolol,Indications of Beta-blockers in CHF,Beta-blocker is indicated in CHF grade II,III and IV irrespective to its cause if not contraindicatedUsed on top of ACEI and diureticsPreferably initiate the treatment in hospital especially for severe casesStart with a very small dose (usually 1/8 of the target dose), and increase gradually in 1-2 week interval.Watch carefully, adjust the dosage of ACEI or diuretics if necessary,Summary of management of H. F.,Treating the underlying cause and associated diseasesGeneral care daily life adjustmentsDrug therapy:ACEIDiuretics in case presence of congestion Beta-blockersDigoxin if necessary,Acute Left Heart FailurePulmonary edema,Etiological causes: Acute myocardial infarction, Hypertension, Mitral stenosis, etc.Pathophysiology marked increase of the pulmonary blood volume and capillary pressure resulting exudation in alveoli.Clinical features: Severe dyspnea Cough with frothy sputum,blood tinged Full of lung rales Restlessness to mental retardation,Management of Acute Left Heart Failure,Oxygen therapy. Positive pressure oxygenation if necessaryVasodilator therapy: Nitroglycerin,nitropruside I.V.Diuretics: Furosemide I.V.Positive inotropic therapy: Dobutamine, milrinone (N.B. cardiac glycoside is contraind
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2024-2034年中国ISTA认证包装测试行业发展潜力预测及投资策略研究报告2
- 2024-2034年中国3-甲基环己醇行业市场深度分析及投资策略咨询报告
- 2024年飞机碳刹车预制件项目发展计划
- 2024年梅酒合作协议书
- 2024-2030年全球及中国氮化硼涂料行业供需态势与产销规模预测报告
- 2024-2030年全球及中国变频电控柜行业前景动态及投资效益预测研究报告
- 2024-2030年全球及中国债券基金销售行业盈利模式与前景动态预测研究报告
- 2024-2030年全球及中国LED灯串行业销售状况及盈利前景预测报告
- 2024-2030年全球与中国陶瓷基复合材料市场竞争态势及销售渠道策略报告
- 2024-2030年全球与中国牡蛎碳酸钙行业发展态势及供需趋势预测报告
- DZT 0338.3-2020 固体矿产资源量估算规程 第3部分 地质统计学法(正式版)
- 2024年陕西省渭南市韩城中考二模地理试题
- 2024年重庆三峰环境产业集团有限公司招聘笔试参考题库含答案解析
- 隔音门检测报告
- 餐饮商业学习协议书范本
- 第六章-公园绿地植物配置与造景.ppt
- (人寿保险)Life Insurance.ppt
- 让造价人员头晕的费用误区——二次次搬运费
- 执行智慧 四大心态
- 戴南污水厂10kV变电所电气设计.doc
- GB 26754-2011 工业叠氮化钠
评论
0/150
提交评论